OVISTA is a clinical screening platform that measures oculomotor behavior — how the eyes move, hold, and inhibit — as an early, objective signal for Alzheimer's disease and frontotemporal dementia.
Typical delay between the first measurable brain changes in Alzheimer's disease and clinical diagnosis.
Time required to complete a single OVISTA oculomotor screening task in a primary care setting.
OVISTA is non-invasive — no blood draw, no imaging, no radiation — using only camera-based eye tracking.
Each protocol targets a different oculomotor circuit — reflexive orienting, executive inhibition, and sustained gaze control — the same networks affected early in neurodegenerative disease. Read the full breakdown →
Measures reflexive response time as gaze moves toward a newly appearing target — a baseline of sensorimotor speed and accuracy.
Requires looking away from a stimulus rather than toward it — a direct probe of executive inhibition, the circuit most sensitive to early impairment.
Measures how precisely gaze holds on a stationary target — instability here reflects declining attentional control.
Every result is expressed against OVISTA's own age- and sex-adjusted normative reference — never against a fixed cutoff pulled from a single study. The output is a calibrated risk band, meant to inform the next clinical step, not replace it.
OVISTA is built for the front door of care — fast enough and affordable enough for a primary care setting, so the right patients get referred sooner. See the full clinician workflow →
A ~5-minute oculomotor test in a family practice or general clinic setting, producing a risk band, not a diagnosis.
Amber or Red results support a referral to neurology or memory-clinic assessment — targeted, not blanket, referral.
Full diagnostic workup remains with specialist care — OVISTA narrows who needs it sooner, it doesn't replace it.
Task timing and structure are grounded in the internationally standardised antisaccade protocol (Antoniades et al., 2013), adapted with published Alzheimer's/MCI-specific evidence where the research calls for it.
Our team's systematic review of the eye-tracking dementia literature — assessing how consistently prior studies report their own methods — informs how rigorously OVISTA documents its own protocols.
Published research tells us which features matter and their expected direction. Individual thresholds come only from OVISTA's own reference data.
OVISTA is currently in pre-clinical development. Our oculomotor protocols are literature-grounded and undergoing pilot validation; they are not yet cleared as a diagnostic device by any regulatory body. We publish this stage honestly because we think it matters as much as the science itself.
Pre-clinical platform, built on a Canadian research foundation, currently focused on Alzheimer's disease and frontotemporal dementia. Supported in part by the Sudbury Catalyst Fund. See the full roadmap →
OVISTA is led from Canada, with research collaborators across cognitive science, clinical psychology, and neurology, and a commercial team based in Canada and the United States. Meet the team →
Whether you're a clinician curious about early access, a researcher interested in the evidence base, or an investor — we'd like to hear from you.